What Penumbra does

Penumbra, Inc. is a publicly traded (NYSE: PEN) medical device company founded in 2004 and headquartered in Alameda, California, that develops and manufactures interventional devices for neurovascular and vascular conditions, primarily focusing on computer-assisted vacuum thrombectomy (CAVT) for the removal of blood clots in stroke, pulmonary embolism, deep vein thrombosis, acute limb ischemia, and coronary occlusion, as well as embolization coils for aneurysms and vessel sacrifice. The company's core technology is the CAVT platform, which combines modulated aspiration algorithms, internal pressure sensors, and the proprietary Penumbra ENGINE aspiration source, capable of delivering nearly pure, continuous vacuum (-29.2 inHg / -98.9 kPa) to detect, fatigue, and ingest clot with minimal catheter manipulation. The product portfolio is anchored by the THUNDERBOLT CAVT platform (the first and only FDA-cleared and CE-marked CAVT for acute ischemic stroke, cleared in June 2026), the RED Reperfusion Catheter family, the Lightning Flash 3.0 system for peripheral thrombectomy, the Indigo Aspiration System (including CAT RX for coronary thrombectomy), and an embolization franchise spanning Ruby coils, POD400, PAC400, PC400, SMART COIL, BENCHMARK access catheters, MIDWAY intermediate catheters, Neuron MAX, and the Artemis neuro evacuation device.

The company sells its single-use medical devices through an enterprise direct field sales force covering 100+ countries with regional offices in the US, Germany, Brazil, Canada, Costa Rica, and Italy, targeting neurointerventional radiologists, interventional radiologists, vascular surgeons, and cardiologists at tertiary and quaternary hospitals with stroke, PE, VTE, and endovascular programs. Revenue is generated through hardware sales of single-use catheters and aspiration source systems to hospitals and healthcare systems under negotiated contracts, with revenue split between thrombectomy products ($947.9M in FY2025) and embolization/access products ($455.7M in FY2025), generating $1,403.7M in full-year 2025 revenue, up 17.5% year-over-year, with $177.7M in net income and a 13.5% operating margin. In January 2026 Boston Scientific announced an agreement to acquire Penumbra for approximately $14.5B ($374 per share, 73% cash/27% stock), and as of mid-2026 the transaction received overwhelming shareholder approval and remained pending regulatory clearance with expected close in 2026.

Name

Penumbra

Legal name

Penumbra, Inc.

Website

https://penumbrainc.com

Company type

Public

Founded year

2004

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Penumbra, Inc. (NYSE: PEN) is a global medical device company that develops computer-assisted vacuum thrombectomy catheters and embolization coils for neurovascular, peripheral vascular, and coronary clot-removal procedures, selling single-use devices directly to hospitals and physicians in 100+ countries.

Ownership category

akta.pro rank

Product category

Interventional Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

Keywords

• Thrombectomy medical devices
• Neurovascular intervention
• Vascular embolization
• Aspiration catheters
• Interventional radiology

Headquarters

HQ city

Alameda

HQ country

United States

HQ region

North America

Offices9 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Thrombectomy Products: Revenue from neuro and peripheral thrombectomy devices including THUNDERBOLT, Penumbra System, RED Reperfusion Catheters, Lightning Flash, Lightning Bolt, and Indigo aspiration catheters. Products sold to hospitals for one-time use in surgical procedures.
2. Embolization and Access Products: Revenue from embolization coils (Ruby, POD, PAC, PC400, SMART COIL) and neuro access catheters (BENCHMARK, MIDWAY, Neuron MAX) for treating aneurysms and vascular conditions.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Penumbra develops, manufactures, and markets interventional medical devices for neurovascular and peripheral vascular conditions. Its core offering is the Computer-Assisted Vacuum Thrombectomy (CAVT) platform powered by the proprietary Penumbra ENGINE, alongside a comprehensive portfolio of neuro and peripheral reperfusion catheters, embolization coils, and access catheters sold to hospitals for use in thrombectomy and embolization procedures.

Product overview

Penumbra is a global healthcare company focused on innovative interventional technologies for treating challenging medical conditions. The company operates two primary product portfolios: Neuro (including Neuro Thrombectomy, Neuro Embolization, Neuro Access Catheters, and Neurosurgical devices) and Vascular (including Peripheral Thrombectomy, Peripheral Embolization, Coronary Thrombectomy, and Vascular Access). The core technology platform is Computer-Assisted Vacuum Thrombectomy (CAVT), powered by the proprietary Penumbra ENGINE aspiration source. Key products include the THUNDERBOLT CAVT platform for stroke, RED Reperfusion Catheters, Lightning Flash 3.0 for peripheral VTE, Indigo System CAT RX for coronary procedures, and comprehensive embolization portfolios including Ruby, POD, PAC, PC400, and SMART COIL systems. The company offers neuro access catheters (BENCHMARK, MIDWAY, Neuron MAX), the Artemis Neuro Evacuation Device for neurosurgery, and the Element Vascular Access System. Products are designed to work together within the Penumbra ecosystem, with the ENGINE serving as the unified aspiration platform across all thrombectomy applications.

Differentiator

Problem solved

Functional benefit

Brands

• THUNDERBOLT: First CAVT (Computer Assisted Vacuum Thrombectomy) platform for acute ischemic stroke treatment using modulated aspiration technology
• Lightning Flash
• Indigo System
• Ruby Embolization Platform
• Swift Coils
• Artemis
• BENCHMARK
• MIDWAY
• ELEMENT
• Penumbra ENGINE

Products and services

• THUNDERBOLT CAVT Platform First computer-assisted vacuum thrombectomy (CAVT) platform for acute ischemic stroke treatment, using proprietary modulated aspiration algorithms to detect, fatigue, and completely remove blood clots with minimal catheter manipulation. Sold to hospitals performing stroke thrombectomy and packaged with RED reperfusion catheters.
• Penumbra System Foundation neuro thrombectomy platform comprising the ENGINE Aspiration Source and compatible reperfusion catheters, generating nearly pure vacuum for blood clot removal in acute ischemic stroke procedures.
• RED Reperfusion Catheters Market-leading neuro reperfusion catheters (RED 62, RED 68, RED 72, RED 72 with SENDit Technology) compatible with the CAVT platform, designed to remove clot during acute ischemic stroke using intentionally sized catheters and deep vacuum.
• 3D Revascularization Device Neuro thrombectomy device with 4 intraluminal chambers designed for enhanced clot engagement and revascularization during stroke procedures.
• ACE Reperfusion Catheters Neuro reperfusion catheters for acute ischemic stroke treatment with advanced tracking technology, used with the Penumbra ENGINE aspiration source.
• Lightning Flash 3.0 Latest generation CAVT system for peripheral thrombectomy and venous thromboembolism (VTE) treatment, featuring advanced software and MaxID technology for efficient clot extraction in peripheral vasculature.
• Lightning Flash 2.0 Previous generation peripheral CAVT system for venous thromboembolism treatment with advanced MaxID technology.
• Lightning Bolt 12 Peripheral CAVT system designed for thrombus removal in arteries and veins with MaxID laser-cut hypotube technology.
• Lightning Bolt 7 Peripheral CAVT system for thrombus removal with advanced tracking technology and MaxID hypotube design.
• Lightning Bolt 6X with TraX Peripheral CAVT system with TraX catheter for enhanced trackability and clot removal capabilities in peripheral vasculature.
• Indigo System CAT RX Coronary mechanical thrombectomy system for removal of fresh, soft emboli and thrombi from coronary and peripheral vasculature using neuro-tracking technology. Used in cardiac catheterization labs for high thrombus burden management prior to PCI.
• CAT 7D Aspiration catheter for peripheral thrombectomy procedures.
• SwiftPAC Coil System Soft, space-seeking liquid metal embolization coil designed to conform to vessels for efficient embolization with lengths ranging from 3-60 cm, used in neurovascular embolization.
• Ruby Embolization Platform Large volume high-density platinum coils designed for arterial and venous embolization in peripheral vasculature, featuring thick and soft coils with 2.2% recanalization rate.
• Ruby Coil XL System Large diameter peripheral embolization coils compatible with diagnostic catheters for vessel occlusion procedures.
• Ruby Coil LP System Low profile peripheral embolization coils designed for precise vessel occlusion with enhanced trackability.
• POD400 and PAC400 System High-volume embolization coil system with POD400 for anchoring and PAC400 for dense packing to complete vessel occlusion in neurovascular procedures.
• PC400 System Neuro embolization system designed for aneurysms from 2-32 mm diameter with complex and helical shapes.
• SwiftSET Coil Detachable coil system for neurovascular embolization with instant mechanical detachment and ultra HD fiber engineering.
• SMART COIL System Advanced neuroembolization coil integrating 10-system features designed to simplify complex neurovascular cases with versatile platform.
• MIDWAY Intermediate Catheters Neuro access catheters available in multiple sizes (MIDWAY 43 and MIDWAY 62) for facilitating therapy in challenging neurovasculature.
• BENCHMARK BMX81 Access System Neuro access catheter with .081 inch ID for intracranial access procedures.
• BENCHMARK BMX96 Access System Neuro access catheter with .096 inch ID for enhanced intracranial access and procedure support.
• BENCHMARK 071 Access System Neuro access catheter with .071 inch ID for intracranial access procedures.
• Neuron MAX 088 Access System Large bore neuro access catheter with .088 inch ID for enhanced access and aspiration capabilities.
• Artemis Neuro Evacuation Device Neurosurgical device for controlled aspiration of tissue and fluid from ventricular system and cerebrum, working with neuroendoscopes through a 19F sheath for intracerebral hemorrhage treatment.
• Element Vascular Access System First laser-cut hypotube sheath designed for venous thromboembolism (VTE) with HemoLock valve system and 17F MaxID technology.

Quantifiable outcome

• Stroke mortality worldwide projected to increase 50% between 2020-2050, making CAVT treatment increasingly critical
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature8 records

Partnerships

Six partnerships are on record, tiered flagship, core and strategic.

• Boston Scientific CorporationflagshipStrategic or Co-development Partner · 15 January 2026Boston Scientific announced agreement to acquire Penumbra for approximately $14.5 billion enterprise value ($374 per share). Transaction combines 73% cash and 27% stock consideration. Expected to close in 2026 pending stockholder and regulatory approvals. Projected to be $0.06-0.08 dilutive to adjusted EPS in first full year, increasingly accretive thereafter with $200 million synergies expected by year three.
• The PERT ConsortiumcoreStrategic or Co-development PartnerPartnership with The PERT Consortium for the STORM-PE randomized controlled trial evaluating CAVT plus anticoagulation versus anticoagulation alone for pulmonary embolism treatment. The consortium brings together pulmonary embolism experts across 22 international sites for clinical research.
• Society of Interventional Radiology (SIR) FoundationcoreStrategic or Co-development PartnerPartnership with SIR Foundation and VIVA Foundation for the EMBOLIZE randomized controlled trial evaluating ovarian vein embolization and pelvic vein embolization for pain reduction in women with pelvic venous disease (PeVD).
• National Blood Clot AlliancestrategicStrategic or Co-development PartnerPartnership through the Get Out the Clot educational initiative to raise awareness about VTE (venous thromboembolism), standardize care, and expand access to innovations for blood clot conditions.
• International Society on Thrombosis and HaemostasisstrategicStrategic or Co-development PartnerPartner in the Get Out the Clot collaborative initiative focused on identifying gaps in patient care related to blood clot conditions and improving outcomes through education and awareness.
• Society for Vascular MedicinestrategicStrategic or Co-development PartnerPartner in Get Out the Clot initiative focused on expanding access to innovations and improving patient outcomes for vascular medicine conditions including VTE.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Cook Medical: Cook Medical manufactures a broad portfolio of interventional devices including catheters and embolization products that compete with Penumbra's vascular access and peripheral intervention offerings. Cook's scale and hospital relationships make it an adjacent competitor.
• Medtronic: Medtronic's Neurovascular business offers Solitaire and other stent retriever and aspiration thrombectomy products for acute ischemic stroke. As a diversified medtech incumbent with massive R&D resources, Medtronic competes with Penumbra across the neurovascular interventional space.
• Abbott Vascular: Abbott offers peripheral and coronary thrombectomy/intervention products (including guide catheters and embolic protection) that overlap with Penumbra's vascular portfolio. Abbott's broader cardiovascular franchise provides scale advantages in hospital contracting and sales force coverage.
• Johnson & Johnson (Cerenovus): Cerenovus (J&J MedTech) offers the EMBOTRAP and CERENOVUS stroke thrombectomy portfolios along with embolization products. J&J's broader healthcare scale and clinical evidence investments make it a direct competitor in both neuro thrombectomy and embolization.

Emerging players

• Vesalio: Vesalio develops the NeVa neurothrombectomy platform for acute ischemic stroke, competing with Penumbra's RED catheters and THUNDERBOLT system. As a focused neurovascular company, Vesalio represents an emerging competitive threat in stroke intervention.
• Imperative Care: Imperative Care develops the Zoom stroke thrombectomy system and other interventional neurovascular devices, directly competing with Penumbra in acute ischemic stroke intervention. As a venture-backed emerging player, it focuses specifically on the neurovascular space where Penumbra's THUNDERBOLT competes.

Regional players

• MicroPort Scientific: MicroPort's neurovascular business offers stent retrievers and aspiration catheters competing in Asian and European markets. While Penumbra has broader US footprint, MicroPort represents a regional competitor in China and other Asia-Pacific geographies.

Direct peers

• AngioDynamics: AngioDynamics offers the AlphaVac and Uni-Fuse mechanical thrombectomy systems for VTE and PE treatment, competing directly with Penumbra's Indigo and Lightning Flash platforms. The companies target the same interventional radiology and vascular surgery customers for peripheral clot removal.
• Merit Medical Systems: Merit Medical offers embolization coils and peripheral intervention products that overlap with Penumbra's Ruby and POD embolization portfolio. Both companies target interventional radiologists for peripheral embolization procedures.
• Stryker (Neurovascular & Inari Medical): Stryker's Neurovascular division and its acquired Inari Medical business compete directly with Penumbra in mechanical thrombectomy for stroke, VTE, and pulmonary embolism. Both companies offer catheter-based clot removal systems targeting the same interventional radiology and vascular surgery customers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/penumbrainc
• YouTubeyoutube.com/@PenumbraInc
• Facebookfacebook.com/penumbraincmedtech
• LinkedInlinkedin.com/company/penumbra-inc
• Instagraminstagram.com/penumbra.inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries3 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Penumbra